Sanjay Popat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8180337/publications.pdf

Version: 2024-02-01

326	14,957	66315	20943
papers	citations	42 h-index	115 g-index

340	340	340	15631
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis. Journal of Clinical Oncology, 2005, 23, 609-618.	0.8	1,574
2	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv192-iv237.	0.6	1,571
3	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	5.1	1,369
4	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology, 2019, 30, 1321-1328.	0.6	842
5	Brigatinib versus Crizotinib in ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039.	13.9	691
6	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet, The, 2021, 397, 375-386.	6.3	638
7	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
8	Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2004, 22, 529-536.	0.8	416
9	Guidelines on the radical management of patients with lung cancer. Thorax, 2010, 65, iii1-iii27.	2.7	393
10	First-Line Afatinib versus Chemotherapy in Patients with Nonâ€“Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology, 2016, 11, 380-390.	0.5	300
11	Novel insights into mesothelioma biology and implications for therapy. Nature Reviews Cancer, 2017, 17, 475-488.	12.8	287
12	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	0.8	277
13	Extraskeletal myxoid chondrosarcoma. Cancer, 2008, 113, 3364-3371.	2.0	272
14	Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€“Naive ALK-Positive Nonâ€“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 2020, 38, 3592-3603.	0.8	224
15	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 2016, 6, 838-851.	7.7	222
16	Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. Journal of Thoracic Oncology, 2010, 5, 436-441.	0.5	196
17	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology, 2020, 15, 803-815.	0.5	178
18	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 435-444.	5.2	172

#	Article	IF	Citations
19	A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology, 2020, 31, 1734-1745.	0.6	163
20	A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. European Journal of Cancer, 2005, 41, 2060-2070.	1.3	161
21	Brigatinib Versus Crizotinib in ALK Inhibitorâ€“Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of Thoracic Oncology, 2021, 16, 2091-2108.	0.5	156
22	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. Journal of Thoracic Oncology, 2021, 16, 764-773.	0.5	128
23	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology, 2017, 35, 3591-3600.	0.8	121
24	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947.	0.5	119
25	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2019, 7, 569-580.	5.2	117
26	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	1.3	112
27	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 895-904.	5.2	111
28	The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 2020, 583, 807-812.	13.7	96
29	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 1254-1262.	5.1	95
30	Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations. PLoS ONE, 2011, 6, e25164.	1.1	77
31	Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. Journal of Thoracic Oncology, 2013, 8, 783-787.	0.5	76
32	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560.	0.5	75
33	Transformation to â€œhigh gradeâ€•neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer, 2013, 80, 1-4.	0.9	72
34	Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1962-1963.	0.5	68
35	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. Journal of Thoracic Oncology, 2016, 11, 1627-1643.	0.5	67
36	Ablative Therapy for Oligometastatic Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 595-606.	1.1	54

#	Article	IF	Citations
37	ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. Lung Cancer, 2012, 75, 300-305.	0.9	52
38	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	2.9	51
39	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE, 2015, 10, e0139074.	1.1	50
40	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2022, 23, 758-767.	5.1	49
41	Afatinib in the treatment of EGFR mutation-positive NSCLC â€“ A network meta-analysis. Lung Cancer, 2014, 85, 230-238.	0.9	47
42	Osimertinib as First-Line Treatment in EGFR-Mutated Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 192-193.	13.9	47
43	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). European Journal of Cancer, 2013, 49, 2815-2822.	1.3	45
44	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer, 2013, 119, 2383-2390.	2.0	45
45	Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.. Journal of Clinical Oncology, 2018, 36, 8515-8515.	0.8	44
46	Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer, 2007, 56, 135-137.	0.9	43
47	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
48	Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open, 2020, 10, e038892.	0.8	42
49	Prevalence of the APC E1317Q variant in colorectal cancer patients. Cancer Letters, 2000, 149, 203-206.	3.2	41
50	Genetic Variants of UGT1A6 Influence Risk of Colorectal Adenoma Recurrence. Clinical Cancer Research, 2006, 12, 6585-6589.	3.2	40
51	A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. Journal of Thoracic Oncology, 2014, 9, 769-774.	0.5	40
52	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. Journal of Clinical Oncology, 2018, 36, 9010-9010.	0.8	40
53	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, 2013, 14, 1765-1777.	0.6	38
54	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1029-1039.	0.5	38

#	Article	IF	Citations
55	Therapy Insight: anthracyclines and trastuzumabâ€"the optimal management of cardiotoxic side effects. Nature Clinical Practice Oncology, 2008, 5, 324-335.	4.3	37
56	Baseline Results of the West London lung cancer screening pilot study â€“ Impact of mobile scanners and dual risk model utilisation. Lung Cancer, 2020, 148, 12-19.	0.9	37
57	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. European Journal of Cancer, 2017, 70, 12-21.	1.3	36
58	Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia, 1999, 13, 1497-1500.	3.3	34
59	Establishing an EGFR mutation screening service for non-small cell lung cancer â€“ Sample quality criteria and candidate histological predictors. European Journal of Cancer, 2012, 48, 61-67.	1.3	34
60	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncology, 2015, 11, 409-420.	1.1	34
61	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. Journal of Clinical Oncology, 2015, 33, 2508-2508.	0.8	32
62	Gut microflora associated characteristics in first-degree relatives of children with celiac disease. Scandinavian Journal of Gastroenterology, 2007, 42, 1204-1208.	0.6	31
63	Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score â‰¥2 â€“ Systematic review and meta-analysis. Lung Cancer, 2021, 158, 97-106.	0.9	31
64	Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis, 2003, 25, 369-373.	1.3	30
65	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 2014, 7, 285.	0.4	30
66	Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership. Lung Cancer, 2015, 89, 175-180.	0.9	30
67	A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. European Journal of Cancer, 2016, 61, 102-110.	1.3	30
68	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 201-216.	1.4	30
69	Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival. Journal of Thoracic Oncology, 2007, 2, 735-740.	0.5	29
70	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung Cancer, 2020, 144, 76-84.	0.9	29
71	Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Research, 2007, 27, 627-33.	0.5	29
72	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. European Journal of Cancer, 2016, 60, 26-39.	1.3	28

#	Article	IF	Citations
73	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clinical Lung Cancer, 2018, 19, 74-83.e11.	1.1	28
74	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature Communications, 2022, 13, .	5.8	28
75	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European Journal of Cancer, 2015, 51, 1511-1528.	1.3	27
76	Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer, 2015, 15, 163.	1.1	25
77	Response evaluation in mesothelioma: Beyond RECIST. Lung Cancer, 2015, 90, 433-441.	0.9	25
78	Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for theÂtreatment of advanced non-small-cell lung cancer. Future Oncology, 2015, 11, 2525-2540.	1.1	25
79	Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting. American Journal of Surgical Pathology, 2020, 44, 347-356.	2.1	25
80	A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer, 2014, 14, 674.	1.1	24
81	3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. European Journal of Cancer, 2015, 51, S711-S712.	1.3	24
82	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer, 2017, 87, 75-83.	1.3	24
83	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. Future Oncology, 2018, 14, 2415-2431.	1.1	24
84	Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. Oncologist, 2021, 26, e306-e315.	1.9	24
85	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 22-27.	0.9	22
86	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Nonâ€“Small Cell Lung Cancer: A Single-Center Experience. Journal of Thoracic Oncology, 2018, 13, 63-72.	0.5	21
87	Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC Cancer, 2006, 6, 150.	1.1	20
88	Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. Journal of Thoracic Oncology, 2010, 5, 1397-1403.	0.5	20
89	A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. Lung Cancer, 2013, 80, 339-340.	0.9	20
90	Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung Cancer, 2019, 134, 117-120.	0.9	20

#	Article	IF	Citations
91	A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung Cancer, 2022, 165, 34-42.	0.9	20
92	Lack of response to nivolumab in a patient with EGFR -mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung Cancer, 2017, 111, 65-68.	0.9	18
93	LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology, 2020, 31, S1211.	0.6	18
94	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer, 2021, 162, 9-15.	0.9	18
95	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. Journal of Clinical Oncology, 2020, 38, 9517-9517.	0.8	18
96	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a â€˜chemosensitiveâ€™ relapse: A single-arm phase II study (EORTC-08061). European Journal of Cancer, 2016, 54, 35-39.	1.3	17
97	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future Oncology, 2017, 13, 1159-1171.	1.1	17
98	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2017, 18, 589-593.	1.1	17
99	Hyperprogression with immunotherapy: Is it real?. Cancer, 2019, 125, 1218-1220.	2.0	17
100	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. Journal of Thoracic Oncology, 2020, 15, 416-425.	0.5	17
101	EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. Journal of Thoracic Oncology, 2020, 15, e162-e165.	0.5	17
102	Systemic therapy for pulmonary carcinoids. Lung Cancer, 2015, 90, 139-147.	0.9	16
103	Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. Histopathology, 2021, 78, 434-444.	1.6	16
104	Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.. Journal of Clinical Oncology, 2020, 38, 9058-9058.	0.8	16
105	Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.. Journal of Clinical Oncology, 2020, 38, TPS1100-TPS1100.	0.8	16
106	Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. BMC Cancer, 2013, 13, 207.	1.1	15
107	Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer, 2017, 111, 51-58.	0.9	15
108	Y disruption, autosomal hypomethylation and poor male lung cancer survival. Scientific Reports, 2021, 11, 12453.	1.6	15

#	Article	IF	Citations
109	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. Journal of Clinical Oncology, 2016, 34, 154-154.	0.8	15
110	Targeting un-MET needs in advanced non-small cell lung cancer. Lung Cancer, 2022, 164, 56-68.	0.9	15
111	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. Frontiers in Oncology, 2022, 12, 834704.	1.3	15
112	Chemotherapy strategies in the treatment of small cell lung cancer. Anti-Cancer Drugs, 2005, 16, 361-372.	0.7	14
113	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. PLoS ONE, 2017, 12, e0186106.	1.1	14
114	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in Oncology, 2019, 46, 145-154.	0.8	14
115	Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.. Journal of Clinical Oncology, 2017, 35, TPS8581-TPS8581.	0.8	14
116	Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. European Journal of Cancer, 2022, 171, 44-54.	1.3	14
117	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). Oncologist, 2022, 27, 255-265.	1.9	13
118	Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Lung Cancer, 2008, 59, 227-231.	0.9	12
119	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer, 2014, 50, 1717-1721.	1.3	12
120	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. Annals of Oncology, 2018, 29, viii497.	0.6	12
121	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitorâ€“naive ALKâ€¯+â€¯nonâ€˜small cell lung cancer (ALTA-1L). Lung Cancer, 2021, 155, 68-77.	0.9	12
122	Integrated genomics point to immune vulnerabilities in pleural mesothelioma. Scientific Reports, 2021, 11, 19138.	1.6	12
123	AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9633-TPS9633.	0.8	12
124	Problems of variable biomarker evaluation in stratified medicine researchâ€”A case study of ERCC1 in non-small-cell lung cancer. Lung Cancer, 2016, 92, 1-7.	0.9	11
125	Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Nonâ€“Small-Cell Lung Cancer. JCO Oncology Practice, 2020, 16, 842-844.	1.4	11
126	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	0.6	11

#	Article	IF	Citations
127	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncology, 2021, 17, 4237-4247.	1.1	11
128	Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. Annals of Human Genetics, 2002, 66, 125-37.	0.3	11
129	A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemotherapy and Pharmacology, 2016, 77, 375-383.	1.1	10
130	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncology, 2019, 15, 1363-1383.	1.1	10
131	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. British Journal of Cancer, 2021, 125, 1210-1216.	2.9	10
132	Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer. Cancer Genetics and Cytogenetics, 2003, 145, 70-73.	1.0	9
133	Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). Journal of the National Cancer Institute, 2005, 97, 1855-1855.	3.0	9
134	Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. Journal of Thoracic Oncology, 2017, 12, 12-14.	0.5	9
135	LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. Annals of Oncology, 2020, 31, S1441.	0.6	9
136	Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer, 2020, 20, 1210.	1.1	9
137	Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2â€tier nuclear grade. Histopathology, 2020, 77, 423-436.	1.6	9
138	Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice. Clinical Oncology, 2020, 32, 527-536.	0.6	9
139	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer, 2022, 167, 8-16.	0.9	9
140	Polymorphic sequence variants in medicine: a challenge and an opportunity. Clinical Medicine, 2003, 3, 260-264.	0.8	8
141	Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers. International Journal of Surgical Pathology, 2005, 13, 127-133.	0.4	8
142	Time Trends in the Outcome of Elderly Patients with Breast Cancer. Breast Journal, 2008, 14, 158-163.	0.4	8
143	A Pilot Study of a Novel Home Telemonitoring System for Oncology Patients Receiving Chemotherapy. Journal of Telemedicine and Telecare, 2013, 19, 148-152.	1.4	8
144	143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7. Journal of Thoracic Oncology, 2018, 13, S84-S85.	0.5	8

#	Article	IF	Citations
145	1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). Annals of Oncology, 2020, 31, S826-S827.	0.6	8
146	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
147	Biomarker Testing for People With Advanced Lung Cancer in England. JTO Clinical and Research Reports, 2021, 2, 100176.	0.6	8
148	Grading in Lung Adenocarcinoma: Another New Normal. Journal of Thoracic Oncology, 2021, 16, 1601-1604.	0.5	8
149	Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, 2016, 90, 280-288.	0.9	7
150	Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. Lung Cancer, 2017, 104, 131-133.	0.9	7
151	Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the WolfÂinÂSheepâ€™s Clothing. Journal of Thoracic Oncology, 2019, 14, 1689-1691.	0.5	7
152	HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung Cancer Management, 2021, 10, LMT48.	1.5	7
153	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer, 2021, 157, 9-16.	0.9	7
154	Lung Cancer in the United Kingdom. Journal of Thoracic Oncology, 2022, 17, 186-193.	0.5	7
155	Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?. Lung Cancer, 2004, 43, 369-370.	0.9	6
156	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clinical Lung Cancer, 2018, 19, 42-50.	1.1	6
157	P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIA Umbrella Trial for Accelerating the Development of Precision Medicines. Journal of Thoracic Oncology, 2019, 14, S755-S756.	0.5	6
158	Pleural mesothelioma (PM) â€“ The status of systemic therapy. Cancer Treatment Reviews, 2021, 100, 102265.	3.4	6
159	Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment. JCO Precision Oncology, 2021, 5, 39-43.	1.5	6
160	Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9084-9084.	0.8	6
161	Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idyllaâ„¢ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib. European Journal of Cancer, 2022, 166, 38-40.	1.3	6
162	Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. Medical Oncology, 2012, 29, 2623-2625.	1.2	5

#	Article	IF	Citations
163	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	1.1	5
164	P2.01: LUME-MeSO: Phase II/III Study ofÂNintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, S216.	0.5	5
165	Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. European Journal of Cancer, 2017, 75, 56-62.	1.3	5
166	MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry. Journal of Thoracic Oncology, 2018, 13, S367.	0.5	5
167	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. Drugs, 2021, 81, 971-984.	4.9	5
168	FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.. Journal of Clinical Oncology, 2013, 31, TPS2626-TPS2626.	0.8	5
169	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9072-9072.	0.8	5
170	Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. Annals of Palliative Medicine, 2014, 3, 19-21.	0.5	5
171	True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. Lung Cancer, 2012, 75, 133-135.	0.9	4
172	The role of afatinib in the management of non-small cell lung carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1529-1539.	1.5	4
173	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Research Notes, 2015, 8, 688.	0.6	4
174	The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 97-104.	1.0	4
175	Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. Future Oncology, 2016, 12, 815-825.	1.1	4
176	First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner isâ€¦. Clinical Oncology, 2017, 29, e1-e4.	0.6	4
177	Do Statins Improve Survival in Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2017, 35, 1497-1498.	0.8	4
178	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 2018, 3, e000408.	2.0	4
179	Lorlatinib Salvages Central Nervous Systemâ€“Only Relapse on Entrectinib in ROS1-Positive NSCLC. Journal of Thoracic Oncology, 2020, 15, e142-e144.	0.5	4
180	Durable response of multiple myeloma and nonâ€small cell lung cancer with simultaneous, biologically targeted treatment. British Journal of Haematology, 2020, 189, e1-e3.	1.2	4

#	Article	IF	Citations
181	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer, 2021, 156, 147-150.	0.9	4
182	Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. Journal of Clinical Oncology, 2019, 37, 9026-9026.	0.8	4
183	Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population. European Journal of Gastroenterology and Hepatology, 2001, 13, 1477-1479.	0.8	3
184	Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 2005, 97, 858-858.	3.0	3
185	Palliative treatments for patients with inoperable gastroesophageal cancers. International Journal of Palliative Nursing, 2006, 12, 306-317.	0.2	3
186	Supersensitive Mutation: Two Case Reports of Nonâ€“Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2010, 11, E5-E8.	1.1	3
187	What exactly are we doing to improve low lung cancer survival in the United Kingdom?. Thorax, 2013, 68, 504-505.	2.7	3
188	76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI). Lung Cancer, 2015, 87, S30.	0.9	3
189	P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S2397.	0.5	3
190	MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. Journal of Thoracic Oncology, 2017, 12, S1884.	0.5	3
191	PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2019, 14, S7.	0.5	3
192	Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. Cancer Treatment and Research Communications, 2020, 25, 100261.	0.7	3
193	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligenceâ€“Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics, 2022, 21, 1020-1029.	1.9	3
194	Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). International Journal of Radiation Oncology Biology Physics, 2014, 90, S5-S6.	0.4	2
195	Understanding lung cancer molecular subtypes. Clinical Practice (London, England), 2014, 11, 441-453.	0.1	2
196	187: National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer. Lung Cancer, 2015, 87, S69-S70.	0.9	2
197	Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers. Annals of Oncology, 2016, 27, vi22.	0.6	2
198	ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)â€“naive, advanced anaplastic lymphoma kinase (ALK)â€“positive nonâ€“small cell lung cancer (NSCLC). Annals of Oncology, 2016, 27, vi448.	0.6	2

#	Article	IF	Citations
199	Management of lung cancer. Medicine, 2016, 44, 244-248.	0.2	2
200	141 HALT trial: stereotactic radiotherapy for oligo-progressive disease (OPD) in oncogene-addicted lung tumours â€“ results of a national trial feasibility questionnaire. Lung Cancer, 2016, 91, S51.	0.9	2
201	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung Cancer, 2017, 111, 6-11.	0.9	2
202	Proactive referral to palliative care: Model of a new integrated palliative care and oncology service. Annals of Oncology, 2017, 28, v640.	0.6	2
203	Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial. Annals of Oncology, 2017, 28, ix74.	0.6	2
204	149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction. Journal of Thoracic Oncology, 2018, 13, S89-S90.	0.5	2
205	Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of Oncology, 2018, 29, viii746.	0.6	2
206	PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial. Journal of Thoracic Oncology, 2018, 13, S186.	0.5	2
207	PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L). Journal of Thoracic Oncology, 2018, 13, S184-S185.	0.5	2
208	213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study. Journal of Thoracic Oncology, 2018, 13, S128.	0.5	2
209	P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L). Journal of Thoracic Oncology, 2019, 14, S411-S412.	0.5	2
210	MA23.10 Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, S345.	0.5	2
211	P2.06-05 Multimodality Therapy Using Total Pleurectomy in Malignant Pleural Mesothelioma: Long-Term Outcomes in 150 Consecutive Cases. Journal of Thoracic Oncology, 2019, 14, S757.	0.5	2
212	1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial. Annals of Oncology, 2020, 31, S840-S841.	0.6	2
213	Brain metastases in solid tumours: new guidelines for a new era. Annals of Oncology, 2021, 32, 1322-1324.	0.6	2
214	Abstract 2243: Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts). , 2016, , .		2
215	Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2016, 34, TPS8574-TPS8574.	0.8	2
216	Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer. Future Oncology, 2022, 18, 2499-2510.	1.1	2

#	Article	IF	Citations
217	[¹⁸F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.. Journal of Clinical Oncology, 2022, 40, 3070-3070.	0.8	2
218	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinaseâ€“positive nonâ€“small cell lung cancer using data from ALEX and final results from ALTA-1L. Current Medical Research and Opinion, 2022, 38, 1587-1593.	0.9	2
219	Malignant pleural mesothelioma: Two cases in first degree relatives. Lung Cancer, 2007, 57, 407-409.	0.9	1
220	Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment. Cancer Treatment Communications, 2015, 4, 86-88.	0.4	1
221	3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice. Lung Cancer, 2016, 91, S2.	0.9	1
222	Phase I dose escalation of pembrolizumab given concurrently with palliative thoracic radiotherapy (RT) for NSCLC. Annals of Oncology, 2018, 29, viii530.	0.6	1
223	Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data. Annals of Oncology, 2018, 29, viii526.	0.6	1
224	Less frequent monitoring of response in patients with advanced thoracic malignancies receiving palliative chemotherapy, does not adversely impact patient care. Lung Cancer, 2018, 115, S42-S43.	0.9	1
225	Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals of Oncology, 2019, 30, vi83.	0.6	1
226	National Optimal Lung Cancer Pathway implementation: can pathologists comply with turnaround times?. Lung Cancer, 2019, 127, S3-S4.	0.9	1
227	The ALK project: a real-world national network and database. Lung Cancer, 2019, 127, S31-S32.	0.9	1
228	Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of Oncology, 2019, 30, ii48.	0.6	1
229	Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma. Annals of Oncology, 2019, 30, ii1.	0.6	1
230	A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. PLoS ONE, 2019, 14, e0225509.	1.1	1
231	1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience. Annals of Oncology, 2020, 31, S1020-S1021.	0.6	1
232	1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience. Annals of Oncology, 2020, 31, S867.	0.6	1
233	1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L. Annals of Oncology, 2020, 31, S843-S844.	0.6	1
234	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612.	0.8	1

#	Article	IF	Citations
235	Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, e23027-e23027.	0.8	1
236	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naÃ¯ve patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2017, 35, 8506-8506.	0.8	1
237	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. Journal of Thoracic Disease, 2014, 6, 356-68.	0.6	1
238	Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC. Cancer Research, 2014, 74, 4657-4657.	0.4	1
239	TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.. Journal of Clinical Oncology, 2015, 33, TPS8109-TPS8109.	0.8	1
240	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. Journal of Clinical Oncology, 2016, 34, e20507-e20507.	0.8	1
241	Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, TPS9098-TPS9098.	0.8	1
242	First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3â€‰Trial. , 2020, 74, .		1
243	A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9â€“15 PROMISE-meso phase III trial. Lung Cancer, 2022, 169, 77-83.	0.9	1
244	Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesotheliomaâ€”Two Case Reports. Journal of Thoracic Oncology, 2008, 3, 539-541.	0.5	0
245	Endocrine manifestations of malignancy. Medicine, 2009, 37, 457-460.	0.2	0
246	The combination of Young's syndrome and small cell lung cancerâ€”A spiky connection?. Lung Cancer, 2010, 67, 372-375.	0.9	0
247	Management of lung cancer. Medicine, 2012, 40, 202-207.	0.2	0
248	Endocrine manifestations ofÂmalignancy. Medicine, 2013, 41, 570-572.	0.2	0
249	38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) â€“ a single institution experience. Lung Cancer, 2014, 83, S15.	0.9	0
250	13 Molecular profiling of non-small cell lung cancer (NSCLC) â€“ the liquid biopsy comes of age. Lung Cancer, 2014, 83, S5.	0.9	0
251	47 The ability of a filter-based antibody-independent approach to capture circulating tumour cells for the diagnosis of lung cancer. Lung Cancer, 2014, 83, S17-S18.	0.9	0
252	8 The utility of peripheral blood circulating tumour cells for the detection of KRAS, EGFR and BRAF mutations in primary lung cancer. Lung Cancer, 2014, 83, S3-S4.	0.9	0

#	Article	IF	Citations
253	3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. European Journal of Cancer, 2015, 51, S626-S627.	1.3	0
254	339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH). European Journal of Cancer, 2015, 51, S67.	1.3	0
255	83: A review of the first 10 months of screening selected patients for the ALK translocation using immunohistochemistry, and their subsequent treatment. Lung Cancer, 2015, 87, S32-S33.	0.9	0
256	186: Forecasting patient recruitment for time-to-event analysis in National Lung Matrix Trial. Lung Cancer, 2015, 87, S69.	0.9	0
257	Never smoker with ground glass opacities on CT. Lancet Respiratory Medicine,the, 2015, 3, 328.	5.2	0
258	Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer (NSCLC): A Network Meta-Analysis vs. New Therapeutic Options. Value in Health, 2016, 19, A711-A712.	0.1	0
259	47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden. Lung Cancer, 2016, 91, S17.	0.9	0
260	72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer. Lung Cancer, 2016, 91, S26.	0.9	0
261	163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma. Lung Cancer, 2016, 91, S59.	0.9	0
262	1 A comparative analysis of cancer hotspot mutation profiles in circulating tumour cells, circulating tumour DNA and matched primary lung tumour. Lung Cancer, 2016, 91, S1.	0.9	0
263	Endocrine manifestations of malignancy. Medicine, 2017, 45, 547-550.	0.2	0
264	OA 03.02 Comprehensive Characterization of Thymic Epithelial Tumor Subtypes Through an Analysis of Somatic Mutations and Copy Number Alterations. Journal of Thoracic Oncology, 2017, 12, S1749.	0.5	0
265	OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1555.	0.5	0
266	PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-NaÃ¯ve Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1577.	0.5	0
267	MTE 09.02 Symptom Experiences and Symptom Clusters in Advanced Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1640-S1641.	0.5	0
268	P3.12-003 Optimized Inhaler Therapy Is Superior to Supportive Care Alone for Dyspnea in Patients with Coexisting COPD and Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S2314-S2315.	0.5	0
269	MA 09.09 Isotoxic Dose-Escalated Radiotherapy (RT) in Non-Small Cell Lung Cancer (NSCLC) with Deep Inspiration Breath Hold (DIBH). Journal of Thoracic Oncology, 2017, 12, S1838.	0.5	0
270	Diagnostic EGFR testing with ctDNA versus tumour in patients with advanced non-small cell lung cancer (NSCLC): The Royal Marsden experience. Annals of Oncology, 2017, 28, ii34-ii35.	0.6	0

#	Article	IF	Citations
271	Targeted Therapy With or Without Dose-intensified Radiotherapy in Oligoprogressive Disease in Oncogene Addicted Lung Tumours. Clinical Oncology, 2018, 30, e64-e65.	0.6	0
272	HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours. Lung Cancer, 2018, 115, S86.	0.9	0
273	Retrospective analysis of outcomes in UK patients with advanced NSCLC and ROS1 rearrangement. Lung Cancer, 2018, 115, S44.	0.9	0
274	KRAS Subtypes in non-small cell lung cancer (NSCLC) within Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1). Lung Cancer, 2018, 115, S6.	0.9	0
275	Lactate dehydrogenase and neutrophil-lymphocyte ratio as clinical predictors of outcome to PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2018, 115, S40.	0.9	0
276	P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy. Journal of Thoracic Oncology, 2018, 13, S588-S589.	0.5	0
277	ES06.02 Integrating New Systemic Therapy into Trials in OMD. Journal of Thoracic Oncology, 2018, 13, S200.	0.5	0
278	P2.06-41 Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC. Journal of Thoracic Oncology, 2018, 13, S758-S759.	0.5	0
279	MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC. Journal of Thoracic Oncology, 2018, 13, S430.	0.5	0
280	Copy number variations in malignant pleural mesothelioma reveal novel regions of genomic imbalances. Lung Cancer, 2018, 115, S27.	0.9	0
281	P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7. Journal of Thoracic Oncology, 2018, 13, S163.	0.5	0
282	Targeted next-generation sequencing of malignant pleural mesothelioma identifies recurrent NRAS oncogene mutations. Lung Cancer, 2018, 115, S26.	0.9	0
283	216PD Should radical surgery be performed in non-epithelioid malignant pleural mesothelioma?. Journal of Thoracic Oncology, 2018, 13, S130.	0.5	0
284	Early proactive referral identifies lung cancer patients with significant palliative care needs. Lung Cancer, 2019, 127, S87.	0.9	0
285	Intratumoral heterogeneity in PD-L1 expression in pleomorphic lung carcinoma: implications for management of stage III disease. Lung Cancer, 2019, 127, S91.	0.9	0
286	Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study. Lung Cancer, 2019, 127, S33-S34.	0.9	0
287	Brigatinib experience on the ALK project. Annals of Oncology, 2019, 30, ii53.	0.6	0
288	S47â€…Impact of number of sampling sites and specimen dimension on the performance of nuclear grade and growth patterns in predicting survival in epithelioid malignant pleural mesothelioma: a single institution review of 614 cases. , 2019, , .		0

#	Article	IF	Citations
289	IBS23.02 Oncological Treatment of Omd in Daily Clinical Practice. Journal of Thoracic Oncology, 2019, 14, S115.	0.5	0
290	MA12.02 Growth Patterns in Epithelioid Malignant Pleural Mesothelioma: A Clinicopathological Review of 614 Cases Over 15 Years. Journal of Thoracic Oncology, 2019, 14, S295-S296.	0.5	0
291	MA23.11 Analysis of Immune Phenotype Composition in Malignant Pleural Mesothelioma (MPM) Using Bulk RNA Sequencing. Journal of Thoracic Oncology, 2019, 14, S345-S346.	0.5	0
292	P2.14-60 Afatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread. Journal of Thoracic Oncology, 2019, 14, S855.	0.5	0
293	P1.04-63 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma. Journal of Thoracic Oncology, 2019, 14, S465-S466.	0.5	0
294	P1.06-08 WDPM-Like but Not Cribriform as Secondary Growth Patterns Modify Survival in Epithelioid Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, S480-S481.	0.5	0
295	MA05.01 Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, S264-S265.	0.5	0
296	Genomic testing in lung cancer: NGS and single gene testing-our experience as a genomics laboratory hub. Lung Cancer, 2020, 139, S63.	0.9	0
297	PD-L1 expression in pleomorphic lung carcinoma with STK11 mutations. Lung Cancer, 2020, 139, S58.	0.9	0
298	HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours. Lung Cancer, 2020, 139, S92.	0.9	0
299	1305P Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L. Annals of Oncology, 2020, 31, S844.	0.6	0
300	1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations. Annals of Oncology, 2020, 31, S860-S861.	0.6	0
301	1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology, 2020, 31, S866.	0.6	0
302	1354P Detection of EGFR T790M in EGFR activating mutation-positive advanced non-small cell lung cancer (NSCLC): Comparison between two assays on circulating tumour (ct)DNA. Annals of Oncology, 2020, 31, S868.	0.6	0
303	395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations. Annals of Oncology, 2020, 31, S1396.	0.6	0
304	420TiP UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib. Annals of Oncology, 2020, 31, S1405-S1406.	0.6	0
305	Squamous Nonâ€“Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of TMPRSS2-ERG Translocation With SOX2 Amplification. JCO Oncology Practice, 2020, 16, 695-697.	1.4	0
306	Stage III non-small cell lung cancer: a UK national survey of practice. Lung Cancer, 2020, 139, S27.	0.9	0

#	Article	IF	Citations
307	Molecular testing for patients with advanced lung cancer in England: real-world evidence from the National Lung Cancer Audit. Lung Cancer, 2020, 139, S62-S63.	0.9	0
308	PET-CT in thoracic oncology: strengths, weaknesses and future directions. Lung Cancer, 2020, 139, S16.	0.9	0
309	An audit of compliance with NOLCP in the GLH era. Lung Cancer, 2021, 156, S27.	0.9	0
310	Detection of tier 1 variants with circulating tumour (ct) DNA next generation sequencing (NGS) in UK non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2021, 156, S28.	0.9	0
311	Molecular Targetable Pathwaysâ€"ALK. , 2022, , 853-864.		0
312	Molecular Targetable Pathways â€“ EGFR. , 2022, , 844-852.		0
313	Platelet counts (PLT) at baseline and on treatment as predictor for progression free survival (PFS) in patients with advanced malignant pleural mesothelioma (MPM): EORTC 08052 study.. Journal of Clinical Oncology, 2013, 31, 7585-7585.	0.8	0
314	A comparative study of blood-based KRAS mutation analysis in circulating tumor cells versus circulating plasma DNA to predict primary tumor mutations in lung cancer.. Journal of Clinical Oncology, 2014, 32, 7563-7563.	0.8	0
315	Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA. , 2015, , .		0
316	Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).. Journal of Clinical Oncology, 2016, 34, e14048-e14048.	0.8	0
317	Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).. Journal of Clinical Oncology, 2016, 34, e20107-e20107.	0.8	0
318	TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. Journal of Clinical Oncology, 2016, 34, TPS9106-TPS9106.	0.8	0
319	Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. , 2016, , .		0
320	Abstract 2627: A study of dynamic changes in PD-L1 expression inKRASmutant adenocarcinoma of the lung exposed to signal transduction inhibitors. , 2017, , .		0
321	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2018, 36, 8568-8568.	0.8	0
322	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. Journal of Clinical Oncology, 2018, 36, 8566-8566.	0.8	0
323	In whom could we diagnose second primary lung cancers â€˜earlyâ€™?. , 2019, , .		0
324	Early response to chemotherapy in malignant pleural mesothelioma assessed using diffusion-weighted MRI: Initial observations. JTO Clinical and Research Reports, 2021, 2, 100253.	0.6	0

#	Article	IF	Citations
325	AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusionâ€“positive advanced/metastatic NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9159-TPS9159.	0.8	0
326	Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L.. Journal of Clinical Oncology, 2022, 40, 9072-9072.	0.8	0